Serological responses and six-month trajectories to COVID-19 Comirnaty and Spikevax booster vaccine, September 2021 to January 2022, London, United Kingdom

Georgina Ireland^{1*}, Heather Whitaker^{2*}, Shamez N Ladhani^{1,5}, Frances Baawuah^{1,3}, Sathyvani Subbarao¹, Suzanne Elgohari¹, Alexandra Smith¹, Michelle O'Brien³, Corinne Whillock¹, Oliver Martin¹, Paul Moss⁴, Mary E Ramsay¹, Gayatri Amirthalingam^{1**}, Kevin E Brown^{1**}

- 1. Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom
- 2. Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom
- 3. Brondesbury Medical Centre, Kilburn, London, United Kingdom
- 4. Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom
- 5. Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom
- * These authors contributed equally to this manuscript
- ** These authors contributed equally and jointly supervised this work

Correspondence: Kevin E Brown (kevin.brown@phe.gov.uk)

Keywords: COVID-19; COVID-Vaccine; Antibody; Spike Protein; Immunity; Pfizer; AstraZeneca, Moderna, Comirnaty, Vaxzevria, Spikevax

Abstract

In contrast to the increasing levels of high avidity S antibody measured by the Roche assay in the first 6 months following natural infection, marked waning is seen post 2 or 3 doses of vaccine. Although the kinetics differ between those with vaccine-induced immunity compared to those infected prior to vaccination (hybrid immunity), waning rates appear to be similar following 2 or 3 doses of vaccine. These data should allow countries to optimise the timing of future doses of vaccine.

In September 2021, the UK Joint Committee on Vaccination and Immunisation (JCVI) recommended a third dose (booster) with either a single dose of Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) or a half dose (50µg) of Spikevax (mRNA-1273, Moderna) for adults aged ≥50 years, individuals aged 16-49 years in clinical risk groups, adult carers and household contacts of immunosuppressed individuals, and frontline health and social care workers, to be offered at least 6 months after their second dose.¹ Following the emergence of the SARS-CoV-2 Omicron variant in December 2021, the booster vaccine programme was extended to all adults (≥18 years) at least 3 months after second dose due to concerns about waning immunity post-primary vaccination, increased transmissibility of the new variant and the winter pressures on the national healthcare system.²

Here we describe antibody kinetics after booster vaccination in adults aged ≥50 years and predict antibody trajectories ≤6 months after booster vaccine. Our findings have important implications for recommendations of further doses of COVID-19 vaccine in boosted adults.

The CONSENSUS audit

In England, the UK Health Security Agency (UKHSA) initiated an evaluation of vaccine responses in adults aged ≥50 years who received the Comirnaty or Vaxzevria (ChAdOx1-S, AstraZeneca) as part of the national immunisation programme to compare short versus longer interval vaccine schedules and monitor antibody waning over time.³ The COVID-19 vaccine responses after extended immunisation schedules (CONSENUS) cohort has been described previously.^{3,4} CONSENSUS recruited immunocompetent adults aged ≥50 years in January 2021 in London to provide serial blood samples after their first dose of COVID-19 vaccine. As part of the national COVID-19 vaccine roll out, participants received either (i) two Comirnaty doses <30 days apart (Comirnaty-control), (ii) two Comirnaty doses ≥30 days apart (Comirnaty-extended) or (iii) two Vaxzevria doses ≥30 days apart (Vaxzevria-extended). Additional blood samples were taken before and after booster vaccine (Comirnaty or Spikevax).

Serum samples were tested for nucleoprotein (N) antibodies as a marker of previous SARS-CoV-2 infection (Elecsys Anti-SARS-CoV-2 total antibody assay, Roche Diagnostics, Basel, Switzerland: positive ≥ 1 COI) and spike (S) protein antibodies, which could be infection- or vaccine-derived (Elecsys Anti-SARS-CoV-2 S total antibody assay, Roche Diagnostics: positive ≥ 0.8 arbitrary units (au)/mL to assess vaccine response). Individuals with ≥ 0.4 (au)/mL on the N assay were considered to have had prior SARS-CoV-2 infection, this was assessed at enrolment and if participants tested N antibody positive after vaccination, indicating vaccine breakthrough, this and subsequent samples were removed from the analysis.

S antibody geometric mean levels (GMLs) were calculated with 95% confidence intervals (CI). Geometric mean ratios (GMR) of responses between timepoints for each vaccine group were estimated using a mixed regression model on log responses including a random effect for each participant. The GMR by vaccine type at each post-vaccination timepoint was estimated via regression on log Roche S responses and included age-group and sex.

Mixed effects linear regression models were used to model log(S antibody) trajectories over time, including a random effect for each individual. Trajectories were compared to convalescent sera taken up to 400 days after PCR-confirmed infection among unvaccinated 15–98-year-olds. Comparing polynomial models using likelihood ratio tests, for the unvaccinated convalescent data log(days since onset) (from day 21) provided the best fit, while among the vaccinated V(days since 2nd vaccination dose) (from day 14) independently provided the best fit for previously infected and infection-naïve adults. A term for dose was further included with the addition of third Comirnaty dose data, so vaccinated models assume that antibody levels follow a parallel rate of waning after doses 2 and 3. As post-booster data are only available to ~3 months after dose 3, data on dose 2 responses supplement predictions of longer-term waning after dose 3. Analyses were carried out using STATA v14.2.

Booster Dose Response

Of the 888 recruited participants, 471 provided serum samples for up to 14 weeks after their booster with Spikevax or Comirnaty (**Table 1**). GMLs increased 2-4 weeks after booster dose for all primary and booster combinations with available data (**Table 2**). In infection-naïve participants, GMLs were 24,901 (95%CI: 10,056-61,663) in Comirnaty-extended/Spikevax, 20,008 (95%CI: 15,463-25,889) in Vaxzevria-extended/Spikevax, 17,703 (95%CI: 13,647-22,965) in Comirnaty-control/Comirnaty, 14,685 (95%CI: 12,611-17,100) in Comirnaty-extended/Comirnaty and 12,015 (95%CI: 13,647-22965) in Vaxzevria-extended/Comirnaty. At 2-4 weeks after the booster GMLs were higher in females but no difference by age was observed. Where pre- and post-booster data were available, GMLs had increased 83.4 fold in Comirnaty-control/Comirnaty, 58.5-fold in Vaxzevria-extended/Comirnaty and 15.3-fold in Comirnaty-extended/Comirnaty vaccinated participants.

Additionally, 66 participants had infection with Wuhan or Alpha before primary vaccination and their GMLs were higher than infection-naïve participants, but post-booster GMRs were greater among the latter. In those with past infection GMLs were highest after Vaxzevria-extended/Comirnaty (49,463, 95%CI:33,658-72,689), followed by Vaxzevria-extended/Spikevax (40,135, 95%CI:27,773-57,998), Comirnaty-control/Comirnaty (33,130, 95%CI: 6,383-17,1950) and Comirnaty-extended/Comirnaty

(21,278, 95%CI:14,190-31,908), with GMLs increasing 13.5-fold in Vaxzevria-extended/Comirnaty and 5-fold each for Comirnaty-control/Comirnaty and Comirnaty-extended/Comirnaty participants.

Post-booster trajectories

For all participants, GMLs peaked 2-4 weeks post-booster and started waning from 5-9 weeks. At 10-14 weeks, GMLs had reduced 65% in Comirnaty-extended/Comirnaty, 49% in Vaxzevria-extended/Comirnaty and 40% in Comirnaty-control/Comirnaty in infection-naïve participants and by 48% in Vaxzevria-extended/Comirnaty, 38% in Comirnaty-extended/Comirnaty and 18% in Comirnaty-control/Comirnaty in previously infected participants (Table 2, Figure 1&2). The post-second and booster dose S-antibody trajectories in infection-naïve and previously-infected participants following Comirnaty-extended primary plus booster differed, with the relative rate of post-second dose decline lower in those who were previously-infected (day 14:182 ratio: 9.5 and 6.5 respectively). Within the infection-naïve and previously-infected cohorts, however, the 3-month rate of decline was similar after second and booster doses (Figure 2b-d). Assuming the same rate of decline as after the second dose, models estimate that at 6 months post-booster vaccine, GMLs would reduce to 2,519 (95%CI: 2,230-2,846) in infection-naïve and 5,945 (95%CI: 4,387-8,057) in previously infected participants.

Whilst post-vaccine antibody levels fell after all vaccine combinations, convalescent sera from clinically mild-to-moderate PCR-confirmed cases (due to Wuhan infecting strain) show that S-antibody GMTs increase for up to 400 days post-infection (Figure 2a). However, GMTs in convalescent sera are significantly lower than post-vaccine, being 172 (95%CI: 132-225) at 365 days post-infection.

Implications of findings

Our results demonstrate a rapid serological response post-booster for all primary immunisation vaccines and schedules, to higher levels than observed after dose 2 of the primary schedule, but waning was observed after 5 weeks. By comparison, there was very little S-antibody waning in naturally-infected, unvaccinated adults up to 365 days after infection. Whilst serological assessment does not take cellular or innate immunity into account, S-antibody responses mirror vaccine efficacy analysis against SARS-CoV-2 infection, hospitalisations and death, even with the emergence of Omicron variant. Additionally, post-booster GMTs in our cohort were similar to those observed in COV-BOOST, a study analysing the vaccine responses to different vaccine combinations.

Our data also highlight differences in people with hybrid-immunity (infection and vaccine) who had higher GMTs at all time-points and less S-antibody waning post-booster. Further work is required to

understand whether trajectories differ in people with post-vaccine breakthrough infections, and are dependant on the variant of infection.

The rapid waning of post-booster antibodies along the same trajectory as two primary immunisation doses indicates that a fourth dose may be required when predictions of future waves coincide with declining protection, particularly in vulnerable groups. However, we do not know the level above which infections or severe disease are prevented. Countries need to decide whether to offer this dose to all adults, as recently announced in Israel, or for higher-risk groups only, such as older adults and those with comorbidities.8 Our trajectory and six-month GML estimates may have utility for policy-makers deciding on the optimal interval for recommending the fourth dose of vaccine, depending on the aim of the programme.

Table 1: Characteristics of CONSENSUS participants with samples <3 weeks before and up to 14 weeks after Comirnaty or Spikevax booster vaccine.

where N is less than 60 percentages haven't been calculated

Vaccine type (primary/secondary)	N	Dose 1-2 schedule median: days (IQR)	Dose 2-3 schedule median: days (IQR)	Age: median (IQR)	Sex: Female			Ethnicity: White		Previously infected	
					n	%	n	%	n	%	
Vaxzevria- extended/ Comirnaty	108	64 (54 - 76)	187 (182 - 193.5)	68 (65 - 71)	62	57.4	90	83.3	17	-	
Vaxzevria- extended/ Spikevax	68	77 (70.5 - 77)	182 (181 - 187.5)	56 (53 - 59)	39	-	57	-	14	-	
Comirnaty- extended/ Comirnaty	219	76 (73 - 77)	187 (182 - 193)	72 (69 - 78)	124	56.6	200	91.3	29	-	
Comirnaty- extended/ Spikevax	10	77.5 (76 - 80)	187 (186 - 203)	57 (50 - 69)	9	-	10	-	0	-	
Comirnaty-control/ Comirnaty	66	21 (21 - 21)	262 (261 - 263	77.5 (75 - 80)	33	-	61	92.4	6	-	


Table 2: Geometric mean levels, including 95% confidence intervals, for CONSENSUS participants, including those infected with SARS-CoV-2 prior to vaccination, boosted with Spikevax and Comirnaty vaccines

					within-individual	within-individual
		time			geometric mean	geometric mean
		sampled		geometric mean levels	ratio of response	ratio of response
Primary	Booster	after dose 3,	n	(95% CI)	relative to 2-4	relative to <3
		weeks		(5570 CI)	wks post dose 3	weeks before dose
		Weeks			(95% CI)	(95% CI)
Vaxzevria	Spikevax	2-4 weeks	49	20008 (15463 - 25889)	(3370 0.1)	(3370 61)
	'	5-9 weeks	5	20048 (10705 - 37545)		
	Comirnaty	<3 before	50	208 (150 - 289)		ref
	,	2-4 weeks	63	12015 (9651 - 14958)	ref	58.5 (40.3 - 85)
		5-9 weeks	15	9525 (6354 - 14279)	0.88 (0.71 - 1.09)	,
		10-14 weeks	59	5209 (4311 - 6295)	0.51 (0.47 - 0.56)	
Comirnaty,	Comirnaty	<3 before	45	194 (138 - 272)	,	ref
schedule < 30	•	2-4 weeks	47	17703 (13647 - 22965)	ref	83.4 (63.1 - 110.2)
days		5-9 weeks	2	,		,
		10-14 weeks	49	8926 (6383 - 12482)	0.6 (0.55 - 0.65)	
Comirnaty	Spikevax	2-4 weeks	5	24901 (10056 - 61663)		
		5-9 weeks	5	17466 (8728 - 34954)		
	Comirnaty	<3 before	120	964 (813 - 1145)		ref
		2-4 weeks	133	14685 (12611 - 17100)	ref	15.3 (13 - 18)
		5-9 weeks	35	11738 (9431 - 14611)	0.77 (0.66 - 0.91)	
		10-14 weeks	149	6305 (5572 - 7134)	0.45 (0.41 - 0.48)	
Infection before	vaccination					
Vaxzevria	Spikevax	2-4 weeks	13	40135 (27773 - 57998)		
	Comirnaty	<3 before	12	3804 (1253 - 11547)		ref
		2-4 weeks	7	49463 (33658 - 72689)	ref	13.5 (8.3 - 21.9)
		5-9 weeks	5	25056 (10498 - 59802)	0.77 (0.58 - 1.03)	
		10-14 weeks	13	12800 (8517 - 19238)	0.52 (0.45 - 0.61)	
Comirnaty,	Comirnaty	<3 before	6	8806 (1309 - 59254)		ref
schedule < 30		2-4 weeks	4	33130 (6383 - 171950)	ref	5 (0.9 - 28.1)
days		5-9 weeks	0			
		10-14 weeks	5	17823 (4926 - 64495)	0.82 (0.78 - 0.85)	
Comirnaty	Spikevax	2-4 weeks	2	17023 (4320 04433)	0.02 (0.70 0.03)	
Committaty	Comirnaty	<3 before	15	5872 (3144 - 10968)		ref
	Committeey	2-4 weeks	18	21278 (14190 - 31908)	ref	5.3 (3.5 - 8)
		5-9 weeks	2	21270 (11130 31300)		(/


GMLs not calculated where 2 or less people within grouping

Figure 1: S antibody trajectory after infection in convalescent serum samples (a), after the second vaccine dose with Comirnaty in CONSENSUS participants by prior infection status (b), and after the second and third vaccine dose with no past SARS-CoV-2 infection before vaccination (c) and with a past infection before vaccination (d).


a) Convalescent serum




b) Second dose trajectories



c) Infection-naïve



d) Previously infected



Acknowledgements

We would like to thank Dorothy Blundell, Dr Caroline Sayer and the team at Haverstock Healthcare GP Federation and the whole CONSESUS and Convalescent sera surveillance team at UK Health Security Agency (UKHSA) including those at Colindale, Manchester and Porton Down who assisted with the laboratory testing.

Funding

This surveillance was funded by PHE now UK Health Security Agency (UKHSA). The CONSENSUS study/audit was approved by the UKHSA R&D Research Ethics and Governance Group. No: NR0253

Conflict of interest

MER reports that the Immunisation and Vaccine Preventable Diseases Division (UKHSA) has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection, which the companies are required to submit to the UK licensing authority in compliance with their risk management strategy. A cost-recovery charge is made for these reports.

Data availability

Applications for relevant anonymised data should be submitted to the UK Health Security Agency Office for Data Release.

References

- 1. The Joint Committee on Vaccination and Immunisation. JCVI issues advice on COVID-19 booster vaccines for those aged 40 to 49 and second doses for 16 to 17 year olds. 2021.
- 2. Department of Health & Social Care. All adults to be offered COVID-19 boosters by end of January. gov.uk; 2021.
- 3. Subbarao S, Warrener LA, Hoschler K, et al. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. *Euro Surveill* 2021; **26**(12).
- 4. Amirthalingam G, Lopez Bernal J, Andrews N, et al. Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England. *Medrxiv* 2021.
- 5. UK Health Security Agency. COVID-19 vaccine surveillance report- Week 6, 2022.
- 6. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med* 2022.
- 7. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021; **398**(10318): 2258-76.
- 8. Burki TK. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med 2022; 10(2): e19.